IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies

Pulmonary Pharmacology and Therapeutics

Volumn 45, Issue , 2017, Pages 95-100

  Passalacqua, Giovanni ^a   Mincarini, Marcello ^a   Colombo, Daniele ^a   Troisi, Giuseppe ^a   Ferrari, Marta ^a   Bagnasco, Diego ^a   Balbi, Francesco ^a   Riccio, Annamaria ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; Eosinophilic inflammation; Idiopathic pulmonary fibrosis; Interleukin 13; Periostin

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; NINTEDANIB; PIRFENIDONE; TRANSCRIPTION FACTOR RUNX2;

ASTHMA; FIBROSING ALVEOLITIS; HUMAN; MUCUS SECRETION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; EOSINOPHIL; IMMUNOLOGY; METABOLISM;

ANIMALS; ASTHMA; EOSINOPHILS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN-13; INTERLEUKIN-4;

EID: 85019178369     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.05.007     Document Type: Review

References (46)

1. [1] Sgalla, G., Biffi, A., Richeldi, L., Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology 21 (2016), 427–437.
2. [2] Vancheri, C., Failla, M., Crimi, N., Raghu, G., Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 35 (2010), 496–504.
3. [3] Puglisi, S., Torrisi, S.E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., et al. New perspectives on management of idiopathic pulmonary fibrosis. Ther. Adv. Chronic Dis. 7 (2016), 108–120.
4. [4] Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C.A., Azuma, A., Behr, J., et al. American thoracic society; European respiratory society; Japanese respiratory society; Latin American thoracic association. an official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 192 (2015), e3–19.
5. [5] Rosas, I.O., Kaminski, N., Update in diffuse parenchymal lung disease. Am. J. Respir. Crit. Care Med. 2015:191 (2013), 270–274.
6. [6] Schaffer, J.M., Singh, S.K., Reitz, B.A., Zamanian, R.T., Mallidi, H.R., Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA 313 (2015), 936–948.
7. [7] Macías-Barragán, J., Sandoval-Rodríguez, A., Navarro-Partida, J., Armendáriz-Borunda, J., The multifaceted role of pirfenidone and its novel targets. Fibrogenes. Tissue Repair, 3, 2010 Sep 1, 16.
8. [8] Myllärniemi, M., Kaarteenaho, R., Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur. Clin. Respir. J., 2, 2015.
9. [9] King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2083–2092.
10. [10] Wollin, L., Wex, E., Pautsch, A., Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45 (2015), 1434–1445.
11. [11] Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2071–2082.
12. ®) trials. Respir. Med. 113 (2016), 74–79.
13. [13] Wilson, M.S., Wynn, T.A., Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2 (2009), 103–121.
14. [14] Jiang, Z., Zhu, L., Update on the role of alternatively activated macrophages in asthma. J. Asthma Allergy 9 (2016 Jun 3), 101–107.
15. [15] Pechkovsky, D.V., Prasse, A., Kollert, F., Engel, K.M., Dentler, J., Luttmann, W., Friedrich, K., Müller-Quernheim, J., Zissel, G., Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal. Clin. Immunol. 137:1 (2010 Oct), 89–101.
16. [16] Parulekar, A.D., Diamant, Z., Hanania, N.A., Role of T2 inflammation biomarkers in severe asthma. Curr. Opin. Pulm. Med. 22 (2016), 59–68.
17. [17] Corren, J., Role of interleukin-13 in asthma. Curr. Allergy Asthma Rep. 13:5 (2013), 415–420.
18. [18] Oh, C.K., Geba, G.P., Molfino, N., Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur. Respir. Rev. 19 (2010), 46–54.
19. [19] Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R.K., Kitani, A., IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12:1 (2006 Jan), 99–106.
20. [20] Chung, K.F., Targeting the interleukin pathway in the treatment of asthma. Lancet 386 (2015), 1086–1096.
21. [21] Andrews, A.L., Nasir, T., Bucchieri, F., Holloway, J.W., Holgate, S.T., Davies, D.E., IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. J. Allergy Clin. Immunol. 118:4 (2006 Oct), 858–865.
22. [22] Izuhara, K., Conway, S.J., Moore, B.B., Matsumoto, H., Holweg, C.T., Matthews, J.G., Arron, J.R., Roles of periostin in respiratory disorders. Am. J. Respir. Crit. Care Med. 193:9 (2016), 949–956.
23. [23] Sterk, P.J., Lutter, R., Asthma phenotyping: TH2-high, TH2-low, and beyond. J. Allergy Clin. Immunol. 133 (2014), 395–396.
24. [24] Li, W., Gao, P., Zhi, Y., Xu, W., Wu, Y., Yin, J., Zhang, J., Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir. Res., 16, 2015, 57.
25. [25] Takayama, G., Arima, K., Kanaji, T., et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118 (2006), 98–104.
26. [26] Sidhu, S.S., Yuan, S., Innes, A.L., et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 14170–14175.
27. [27] Gao, P., Simpson, J.L., Zhang, J., Gibson, P.G., Galectin-3: its role in asthma and potential as an anti-inflammatory target. Respir. Res., 14, 2013, 136.
28. [28] Zuberi, R.I., Hsu, D.K., Kalayci, O., Chen, H.Y., Sheldon, H.K., Yu, L., et al. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am. J. Pathol. 165 (2004), 2045–2053.
29. [29] Mauri, P., Riccio, A.M., Rossi, R., Di Silvestre, D., Benazzi, L., De Ferrari, L., Dal Negro, R.W., Holgate, S.T., Canonica, G.W., Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol. Lett. 162:1 Pt A (2014 Nov), 2–10.
30. [30] MacKinnon, A.C., Gibbons, M.A., Farnworth, S.L., Leffler, H., Nilsson, U.J., Delaine, T., et al. Regulation of TGF-β1 driven lung fibrosis by Galectin-3. Am. J. Respir. Crit. Care Med. 185 (2012), 537–546.
31. [31] Henderson, N.C., Mackinnon, A.C., Farnworth, S.L., Poirier, F., Russo, F.P., Iredale, J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5060–5065.
32. [32] Henderson, N.C., Mackinnon, A.C., Farnworth, S.L., Poirier, F., Russo, F.P., Iredale, J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5060–5065.
33. [33] Mahendran, S., Sethi, T., Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?. QJM 105:10 (2012 Oct), 929–934.
34. [34] Zhu, Z., Homer, R.J., Wang, Z., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103 (1999), 779–788.
35. [35] Belperio, J.A., Dy, M., Burdick, M.D., et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 27 (2002), 419–427.
36. [36] Hancock, A., Armstrong, L., Gama, R., Millar, A., Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am. J. Respir. Cell Mol. Biol. 18 (1998), 60–65.
37. [37] Jakubzick, C., Choi, E.S., Carpenter, K.J., Kunkel, S.L., Evanoff, H., Martinez, F.J., Flaherty, K.R., Toews, G.B., Colby, T.V., Travis, W.D., et al. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am. J. Pathol. 164 (2004), 1989–2001.
38. [38] Park, S.W., Ahn, M.H., Jang, H.K., Jang, A.S., Kim, D.J., Koh, E.S., et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J. Korean Med. Sci. 24 (2009), 614–620.
39. [39] Murray, L.A., Zhang, H., Oak, S.R., Coelho, A.L., Herath, A., Flaherty, K.R., et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am. J. Respir. Cell Mol. Biol. 50 (2014), 985–994.
40. [40] Okamoto, M., Hoshino, T., Kitasato, Y., Sakazaki, Y., Kawayama, T., Fujimoto, K., et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur. Respir. J. 37 (2011), 1119–1127.
41. [41] Uchida, M., Shiraishi, H., Ohta, S., Arima, K., Taniguchi, K., Suzuki, S., et al. Periostin, A matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 46 (2012), 677–686.
42. [42] A phase 2, multicenter, double-blind within cohort, dose-escalation study to evaluate the safety and tolerability of multiple doses of CAT-354 (Tralokinumab) in japanese patients with idiopathic pulmonary fibrosis. NCT02036580. https://clinicaltrials.gov. Last accessed April 2016.
43. [43] A phase 2, randomized dose-ranging study to evaluate the efficacy of Tralokinumab in adults with idiopathic pulmonary fibrosis. NCT01629667. https://clinicaltrials.gov. Last accessed April 2016.
44. [44] A phase II, randomized, double-blind, placebo-controlled, study to assess the efficacy and safety oh Lebrikizumab in patients with idioipathic pulmonary fibrosis. NCT01872689. https://clinicaltrials.gov. Last accessed April 2016.
45. [45] Komiya, K., Ohta, S., Arima, K., Ogawa, M., Suzuki, S., et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. Respir. Res., 18(1), 2017 Feb 20, 37.
46. [46] Rafii, Rokhsara, Juarez, Maya M., Albertson, Timothy E., Chan, Andrew L., A review of current and novel therapies for idiopathic pulmonary fibrosis. J. Thorac. Dis. 5:1 (2013 Feb), 48–73, 10.3978/j.issn.2072-1439.2012.12.07.